Zydus Cadila (Cadila Healthcare Lltd), on Wednesday, said it has received final approval from the USFDA to market Amantadine Hydrochloride capsules USP, 100 mg.
Estimated sales for this drug is $40.1 million. The drug, which is used in the treatment of Parkinson’s disease and select viral infections, will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
The company stock was trading down by 0.79 per cent at Rs 333.50 on the BSE.